

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/732,597	12/08/2000	Edgar B. Cahoon	BB1413 US NA	2801
23906 7:	590 08/07/2002			
E I DU PONT	DE NEMOURS ANI	EXAMINER		
	NT RECORDS CENTEI L PLAZA 25/1128	MCELWAIN, ELIZABETH F		
4417 LANCAS				
WILMINGTO			ART UNIT	PAPER NUMBER
	•		1638	(
			DATE MAILED: 08/07/2002	\wp

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)		
Office Action Summary				CAHOON ET AL.		
		09/732,597 Examiner		Art Unit		
		Elizabeth McElw	voin	1638		
	The MAILING DATE of this communication app					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)	Responsive to communication(s) filed on 08 L	December 2000 .				
2a)□		nis action is non-fi	nal.			
3)	<u> </u>					
Disposition of Claims						
4) Claim(s) 1-26 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.					
8) Claim(s) 1-26 are subject to restriction and/or election requirement.						
Applicati	on Papers					
9) 🔲 🗆	The specification is objected to by the Examine	er.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the	e drawing(s) be he	ld in abeyance. Se	ee 37 CFR 1.85(a).		
11) 🔲 🛚	The proposed drawing correction filed on			ved by the Examiner		
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) _	4)		(PTO-413) Paper No(s) Patent Application (PTO-152)		

5

10

15

20

Applicants are reminded that nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute **independent and distinct** inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

Upon election of a Group below, Applicant is additionally required to select a pair of sequences consisting of a single nucleotide sequence that encodes a single amino acid sequence, when the group has claims drawn to sequences. This requirement is not to be construed as a requirement for an election of species, since each nucleotide and amino acid sequence is not a member of single genus of invention, but constitutes an independent and patentably distinct invention.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-13, 21-23, 25 and 26, drawn to DNA, cells and plants transformed therewith, classified in class 800, subclass 298, for example.
- II. Claims 14 and 15, drawn to a method of producing a polynucleotide fragment by synthesis, classified in class 536, subclass 23.1, for example.
- III. Claim 16-20, drawn to polypeptide, classified in class 530, subclass 370, for example.
- IV. Claim 24, drawn to oil, classified in class 426, subclass 601, for example.

Serial No. 09/732,597 Art Unit 1638

-3-

The inventions are distinct, each from the other because:

The inventions of Groups I-IV are distinct products and methods, wherein one is not required by the other. The DNA of Group I can be made by a method other than that of Group II such as by cloning, and is not required for the protein of Group III, which can be made by chemical synthesis, not requiring the DNA. The products of Groups I, III and IV are each distinct products one from each of the others that differ chemically, structurally and functionally. In addition, the oil of Group IV is not required by the method of Group II. Thus the inventions of Groups I-IV are each capable of being separately made, independently used and the patentability of one would not render the other obvious or unpatentable.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, their recognized divergent subject matter, and the requirement for different areas of search, restriction for examination purposes as indicated is proper.

15

20

5

10

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

-4-

Art Unit 1638

5

10

15

application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth F. McElwain whose telephone number is (703) 308-1794. The examiner can normally be reached on Monday through Friday from 8:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (703) 306-3218. The fax phone number for this Group is (703) 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Any inquiry of a general nature or relating to the status of this application should be directed to the legal analyst, Gwendolyn Payne, whose telephone number is (703) 305-2475, or to the Group receptionist whose telephone number is (703) 308-0196.

Elizabeth F. McElwain, Ph.D. August 2, 2002

ELIZABETH F. MCELWAIN PRIMARY EXAMINER GROUP 1800